Sachs C. David's Insider Trades & SAST Disclosures
Sachs C. David's most recent trade in ImmunityBio Inc was a trade of 40,650 Common Stock done . Disclosure was reported to the exchange on Feb. 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sachs C. David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 40,650 | 241,480 | - | 0 | Common Stock | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 40,650 | 81,301 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 22 Feb 2025 | 15,860 | 225,620 | - | 3.4 | 54,241 | Common Stock |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 843,750 | 843,750 | - | - | Stock Option (right to buy) | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 246,710 | 246,710 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 30,397 | 75,999 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 30,397 | 216,235 | - | 0 | Common Stock | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.56 per share. | 31 Dec 2024 | 15,405 | 200,830 | - | 2.6 | 39,437 | Common Stock |
| ImmunityBio Inc | Sachs David C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 424,390 | 424,390 | - | - | Stock Option (right to buy) | |
| ImmunityBio Inc | David Sachs C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 121,951 | 121,951 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David Sachs C. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 70,745 | 212,673 | - | 0 | Common Stock | |
| ImmunityBio Inc | David Sachs C. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 70,745 | 0 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | Sachs C. David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.36 per share. | 31 Jan 2024 | 26,835 | 185,838 | - | 3.4 | 90,166 | Common Stock |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 30,397 | 106,396 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | Sachs C. David | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 30,397 | 152,439 | - | 0 | Common Stock | |
| ImmunityBio Inc | C. Sachs David | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.02 per share. | 31 Dec 2023 | 10,511 | 141,928 | - | 5.0 | 52,765 | Common Stock |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2023 | 141,489 | 141,489 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 7,598 | 136,793 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 7,598 | 51,298 | - | 0 | Common Stock | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 17,242 | 43,700 | - | 0 | Common Stock | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 17,242 | 144,391 | - | - | Restricted Stock Units | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2021 | 7,598 | 26,458 | - | 0 | Common Stock | |
| ImmunityBio Inc | David C. Sachs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2021 | 7,598 | 161,633 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges